Renovaro INC Form 4 insider transactions

Director William Anderson Wittekind reports a transfer of 350,000 shares and adjustments to his beneficial ownership in Renovaro Inc.

Renovaro Inc. and Predictive Oncology Inc. amend their letter of intent, extending the acquisition deadline to March 31, 2025, and involving further share purchases by Renovaro.

Director Maurice van Tilburg reports acquisition of Renovaro Inc. shares and options.

Nathen Fuentes, CFO of Renovaro Inc., reports the acquisition of options to purchase 250,000 shares of common stock.

Mark Anthony Collins, a director of Renovaro Inc., acquired options to purchase 120,968 shares of common stock on November 4, 2024.

Director Douglas W. Calder reports acquisition of options to purchase 120,968 shares of Renovaro Inc. common stock.

Interim CFO of Renovaro Inc., Simon Tarsh, reports the acquisition of options to purchase 58,500 shares of common stock.

James A. McNulty, a director of Renovaro Inc., acquired options to purchase 120,968 shares of common stock on November 4, 2024.

David Hershel Weinstein, CEO of Renovaro Inc., reports acquisition of shares and options in the company.

Director William Anderson Wittekind reports a sale of Renovaro Inc. shares and updates on beneficial ownership, including holdings through various entities and trusts.

Director Avram Miller forfeited 833,333 unvested shares of Renovaro stock in exchange for a new option to purchase 978,261 shares.

Karen Brink, a director and 10% owner of Renovaro Inc., amends a previous Form 4 filing to clarify the ownership of 2,000,000 common shares held indirectly through Yalla Yalla Ltd.

Director Karen Brink reports the transfer of 2,000,000 common shares from Yalla Yalla Ltd., an entity she ultimately benefits from, to another entity as payment for consulting services.

Director William Anderson Wittekind reported the sale of 16,362 shares of Renovaro Inc. common stock at an average price of $1.46.

William Anderson Wittekind, a director and 10% owner of Renovaro Inc., files an amendment to correct the number of shares held by Weird Science LLC after a sale reported on July 15, 2024.

William Anderson Wittekind, a director and 10% owner of Renovaro Inc., files an amendment to a previous Form 4 to correct the number of shares held by Weird Science LLC after a sale on July 11, 2024.

Director William Anderson Wittekind reported the sale of 21,954 shares of Renovaro Inc. common stock at an average price of $1.41.

Director William Anderson Wittekind reports multiple sales of Renovaro Inc. common stock between July 9th and July 11th, 2024.

Director William Anderson Wittekind reports selling shares of Renovaro Inc. on July 3rd and 5th, 2024.

Director William Anderson Wittekind reports selling Renovaro Inc. shares on July 1st and 2nd, 2024.

Karen Brink, a director and 10% owner of Renovaro Inc., reports the transfer of 1,853,517 common shares from Yalla Yalla Ltd., an entity she beneficially owns, to other entities as payment for services.

Director Avram Miller acquired options to purchase 18,634 shares of Renovaro Inc. common stock at $1.61 per share.

Director William Anderson Wittekind reports the sale of Renovaro Inc. shares across multiple transactions.

Director Ruud Hendriks reports acquiring options to purchase 18,634 shares of Renovaro Inc. common stock at $1.61 per share on June 25, 2024.

Director James Sapirstein reports acquisition of Renovaro Inc. shares through option exercise on June 25, 2024.

Carol L Brosgart, a director of Renovaro Biosciences, acquired options to purchase 42,857 shares of common stock on June 25, 2024.

Director Jayne McNicol reports acquisition of options to purchase 46,584 shares of Renovaro Inc. common stock.

Gregg H. Alton, a director of Renovaro Biosciences Inc., acquired options to purchase 48,137 shares of common stock on June 25, 2024.

Director Rene Sindlev reports acquisition of options to purchase 62,112 shares of Renovaro Inc. common stock.

Director William Anderson Wittekind of Renovaro Inc. reports the sale of 50,000 shares of common stock at an average price of $1.58.